Alector vs X4 Pharmaceuticals
X4 Pharmaceuticals is the larger business, with $35.1m of revenue in fiscal 2025 against $21.0m for Alector (1.7 times as much). X4 Pharmaceuticals grew faster (1250.5% against -79.1%). X4 Pharmaceuticals kept more of each dollar of sales as profit: a net margin of -225.6% against -679.2%. Alector carries less debt relative to equity (33.8% against 40.3%).
| Latest fiscal year | AlectorALEC, 2025 | X4 PharmaceuticalsXFOR, 2025 |
|---|---|---|
| Revenue | $21.0m | $35.1m |
| Revenue growth | -79.1% | 1250.5% |
| Net income | −$143m | −$79.2m |
| Operating margin | -741.3% | -247.4% |
| Net margin | -679.2% | -225.6% |
| Return on equity | -181.6% | -76.0% |
| Free cash flow | −$184m | −$85.6m |
| Cash | $65.8m | $217m |
| Total debt | $10.4m | $75.0m |
| Debt to equity | 33.8% | 40.3% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 103 | 45 |
| Market value | $229m | $308m |
| Price vs our value range | — | — |
| Moat score | 9 (Weak) | — |
| Insider trades, 12 months | 0 buys, 21 sales | 1 buys, 5 sales |